Astellas DRC Phase 1b, Dose Escalation Evaluation of Safety and Tolerability and a Ph 2, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to AMD
Research Grant
Awarded By
Astellas Institute for Regenerative Medicine
Start Date
March 30, 2017
End Date
April 30, 2021
Awarded By
Astellas Institute for Regenerative Medicine
Start Date
March 30, 2017
End Date
April 30, 2021